NARA Discovery
Article Details
← Back to Search Results
Journal Article

Episodic Ataxia Type 1: Natural History and Effect on Quality of Life

Tracey D. Graves; Robert C. Griggs; Brian N. Bundy; Joanna C. Jen; Robert W. Baloh; Michael G. Hanna; Joanna J. Jen; Anthony A. Amato; Richard J. Barohn; Angelika F. Hahn; Kimberly Hart; Barbara Herr; Yunxia Wang; Mohammad Salajegheh; Araya Puwanant; Sanjeev Rajakalendran; Yoon-Hee Cha; Jeffrey Krischer; Laura Herbelin; Kristen Roe; Joseph Gomes; Holly Ruhlig; Bonnie Patterson; David Cuthbertson; Rachel Richesson; Jennifer Lloyd
The Cerebellum · Vol. 22, Issue 4 · pp. 578-586 · 2022

Abstract

Episodic ataxia type 1 (EA1) is a rare autosomal potassium channelopathy, due to mutations in KCNA1 . Patients have childhood onset of intermittent attacks of ataxia, dizziness or imbalance. In order to quantify the natural history of EA1, its effect on quality of life and in preparation for future clinical trials, we set up an international multi-centre study of EA1. We recruited thirty-three participants with EA1: twenty-three completed 1-year follow-up and eighteen completed 2-year follow-up. There was very little accumulation of disability or impairment over the course of the 2 years of the study. The outcome measures of ataxia (SARA and functional rating of ataxia) and the activities of daily living scale were largely stable over time. Self-reported health-related quality of life (SF-36) scores were lower across all domains than controls, in keeping with a chronic condition. Physical subdomain scores appeared to deteriorate over time, which seems to be driven by the female participants in the study. This is an interesting finding and warrants further study. Attacks of EA1 reported by participants in real time via an interactive voice response system showed that symptoms were not stereotyped; however, attack duration and frequency was stable between individuals. This large prospective study is the first ever completed in subjects with EA1. We document the natural history of the disorder over 2 years. These data will enable the development of outcome measures for clinical trials of treatment.

Bibliographic Information

JournalThe Cerebellum
PublisherSpringer
Publication Date2022-06-03
Publication Year2022
Volume22
Issue4
Pages578-586
Document TypeJournal Article
eISSN1473-4230
DOI10.1007/s12311-021-01360-6

Access Information

NARA Access Coverage2002-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12311
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.